[CAS NO. 1383718-29-3] NecroX-5
PRODUCTS SPECIFICATIONS [1383718-29-3]
DESCRIPTION [1383718-29-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 645.81 |
| Molecular Formula | C27H39N3O9S3 |
| SMILES | O=S1(CCN(CC2=CC3=C(NC(C4=CC=CC=C4)=C3)C(NCC5CCOCC5)=C2)CC1)=O.CS(=O)(O)=O.CS(=O)(O)=O |
1 Publications Citing Use of MCE
Summary
NecroX-5 is a derivative of the NecroX, reduces intracellular calcium concentration, and possesses anti-inflammatory and anti-cancer activity.
IC50 & Target
Calcium channel [1]
In Vitro
NecroX-5 (10 or 40 μM) inhibits breast cancer cell migration, which is correlated with mitoROS reduction, and mediated by AKT inhibition. NecroX-5 (10 μM) decreases intracellular calcium concentration in 4T1 cells by blocking Ca 2+ influx, which mediated the inhibition of cell migration, AKT downregulation and the reduction of mitochondrial ROS levels [1] . NecroX-5 (10 µM) treatment for 24 h, effectively decreases the increased TNFα, TGFβ1, pSmad2 and the expression of Dcn in LPS-stimulated H9C2 cells [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
NecroX-5 (2.5 mg/kg, everyday other day) inhibits breast cancer cell metastasis in TUBO-P2J tumour-bearing mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : 170 mg/mL ( 263.24 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.5484 mL | 7.7422 mL | 15.4844 mL |
| 5 mM | 0.3097 mL | 1.5484 mL | 3.0969 mL |
| 10 mM | 0.1548 mL | 0.7742 mL | 1.5484 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.83 mg/mL (4.38 mM); Clear solution
References
- [1] Park JH, et al. NecroX-5 prevents breast cancer metastasis by AKT inhibition via reducing intracellular calcium levels. Int J Oncol. 2017 Jan;50(1):185-192.
- [2] Thu VT, et al. NecroX-5 exerts anti-inflammatory and anti-fibrotic effects via modulation of the TNFα/Dcn/TGFβ1/Smad2 pathway in hypoxia/reoxygenation-treated rat hearts. Korean J Physiol Pharmacol. 2016 May;20(3):305-14.
